Galectin Therapeutics Inc. (GALT)

US — Healthcare Sector
Peers: MDGL  SCPH  AKRO  GLMD  VSTM  VKTX 

Automate Your Wheel Strategy on GALT

With Tiblio's Option Bot, you can configure your own wheel strategy including GALT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol GALT
  • Rev/Share 0.0006
  • Book/Share -1.8467
  • PB -2.2933
  • Debt/Equity -1.0285
  • CurrentRatio 1.4319
  • ROIC -6.9705

 

  • MktCap 271256671.0
  • FreeCF/Share -0.5614
  • PFCF -7.6153
  • PE -6.661
  • Debt/Assets 7.724
  • DivYield 0
  • ROE 0.3797

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed GALT H.C. Wainwright -- Buy -- $6 June 17, 2025

News

Galectin Therapeutics Inc. (GALT) Is Up 7.48% in One Week: What You Should Know
GALT
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive

Does Galectin Therapeutics Inc. (GALT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Read More
image for news Galectin Therapeutics Inc. (GALT) Is Up 7.48% in One Week: What You Should Know
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
GALT
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

NORCROSS, Ga., May 12, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, presented a late-breaking oral presentation of the NAVIGATE study analysis at the EASL 2025 Congress, on May 10, 2025, in Amsterdam, Netherlands. The NAVIGATE study evaluated belapectin, a galectin-3 inhibitor, in patients with MASH cirrhosis and portal hypertension.

Read More
image for news Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress

About Galectin Therapeutics Inc. (GALT)

  • IPO Date 2002-09-04
  • Website https://galectintherapeutics.com
  • Industry Biotechnology
  • CEO Joel Lewis CPA
  • Employees 15
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.